User: A 17-year-old girl with a history of anxiety and anorexia nervosa presented to a local medical center with anxiety, malaise, lightheadedness, and palpitations. She had started an intensive outpatient nutritional rehabilitation program 2 weeks earlier and had presented to that same hospital 1 week before the current presentation with similar symptoms. At the time of that visit, her potassium level was 2.7 mmol per liter, but the results of other laboratory studies were normal. Oral potassium supplementation was provided, and she was discharged home with a prescription for 20 mEq of potassium chloride daily. However, at the time of her current presentation, she was found to have hypokalemia, hypophosphatemia, and hypomagnesemia. She received oral and parenteral electrolyte replacement and was transferred to the emergency department of an academic medical center for further care.
Two years before presentation, the patient had received a diagnosis of anorexia nervosa. At that time, she had reported fear of gaining weight and associated restrictive eating, laxative use, and hyperexercising but no purging behavior or diuretic abuse. Individual therapy that was focused on her eating disorder had led to improvement in her eating behavior and weight restoration, such that at that time her weight was 59 kg and her body-mass index (BMI) was 22.8. However, during the Covid-19 pandemic, she struggled with mood regulation and re-engaged in caloric restriction and hyperexercise, although she stated that she was not purging or taking laxatives, diet pills, or diuretics. Consequently, in the preceding month she had lost 5.9 kg. She opted to participate in a treatment program for persons with eating disorders, which was conducted virtually owing to restrictions regarding personal contact during the pandemic. On starting the program, she immediately increased her caloric intake from <1000 kcal per day to >2000 kcal per day, which resulted in a rapid weight gain of 3.2 kg. She noted a long history of low mood, anhedonia, lethargy, hypersomnia, and feelings of excessive guilt and worthlessness, for which her primary care physician had recently prescribed sertraline and recommended psychotherapy. She took no other medications and had no other significant medical history. She reported no use of tobacco, illicit drugs, or alcohol and had no fevers, chest pain, vomiting, diarrhea, or abdominal pain.
Hello, Chief Resident here.
This is a 17-year-old female with a history of anorexia nervosa who presents with a constellation of electrolyte abnormalities (hypokalemia, hypophosphatemia, and hypomagnesemia) and cardiovascular symptoms (palpitations, lightheadedness).
Key Findings:
1. Rapid Nutritional Rehabilitation: She increased caloric intake from <1000 kcal to >2000 kcal/day over two weeks.
2. Rapid Weight Gain: 3.2 kg gain in a very short period, likely representing fluid shifts and glycogen storage.
3. Triad of Electrolyte Depletion: Profound hypokalemia (2.7 mmol/L initially, recurring despite supplementation), hypophosphatemia, and hypomagnesemia.
4. Psychiatric Comorbidity: History of anxiety, depression, and recent initiation of sertraline (SSRI).
5. Absence of Purging: Patient denies vomiting, laxative, or diuretic use, though these must be considered in the context of an eating disorder.
To refine the diagnosis and ensure patient safety, I recommend the following:
Management Note: Caloric intake should be temporarily reduced and then titrated upward more slowly while aggressively replacing electrolytes to prevent cardiac failure or Wernicke’s encephalopathy (ensure Thiamine is administered).
Hello Attending Consultant here.
Critique of resident plan (5 points):
Overstated refeeding probability (75%): While plausible, the persistent/recurrent hypokalemia despite supplementation and the 2-week delay after caloric increase favor surreptitious purging or occult diuretic use over classic acute refeeding syndrome; adjust Bayesian weighting to ~40-50%.
Missing core refeeding labs: Omit serum prealbumin, thiamine level, and daily phosphate/glucose trends; these are mandatory to quantify refeeding risk and prevent Wernicke encephalopathy or respiratory failure.
Incomplete ECG specification: Request full 12-lead ECG with manual QTc measurement (Bazett or Fridericia) plus telemetry; do not limit to “assess for U-waves.”
Urine studies insufficiently targeted: Add spot urine diuretic screen (furosemide, thiazides) and urine pH/osmolality; fractional excretion calculations alone will not exclude laxative abuse.
Caloric adjustment premature: Do not recommend immediate caloric reduction without first confirming absence of Wernicke risk and stabilizing Mg²⁺ (>0.8 mmol/L) and PO₄ (>0.5 mmol/L); follow ASPEN refeeding guidelines with 10-20 kcal/kg/day start.
Sertraline interaction overlooked: SSRI initiation can exacerbate anxiety-driven restriction or unmask QTc prolongation when combined with electrolyte derangement; document baseline QTc before dose titration.
No multidisciplinary handoff: Immediate involvement of eating-disorder specialist, dietitian, and psychiatry is required; resident plan lacks explicit care-team activation.
Hello, Expert Clinician here.
The most likely unifying diagnosis is Refeeding Syndrome. This condition is characterized by electrolyte imbalances, particularly hypophosphatemia, hypokalemia, and hypomagnesemia, following the reintroduction of nutrition after a period of malnutrition or starvation. The patient's rapid increase in caloric intake and subsequent electrolyte abnormalities strongly suggest this diagnosis.
Refeeding Syndrome:
- Fits: The patient increased her caloric intake significantly, leading to rapid weight gain and the classic triad of electrolyte disturbances. The timeline and symptoms (palpitations, lightheadedness) align with this condition.
- Does Not Fit: Persistent hypokalemia despite supplementation could suggest another underlying issue, but the overall picture is consistent with refeeding syndrome.
Surreptitious Purging or Diuretic/Laxative Abuse:
- Fits: Persistent hypokalemia and hypomagnesemia could be due to ongoing purging behaviors, which are common in eating disorders.
- Does Not Fit: The patient denies these behaviors, and hypophosphatemia is more indicative of refeeding syndrome.
Gitelman or Bartter Syndrome:
- Fits: These conditions cause renal potassium and magnesium wasting, leading to similar electrolyte imbalances.
- Does Not Fit: The acute presentation following nutritional rehabilitation is more suggestive of refeeding syndrome.
The key pivot in this case is the rapid increase in caloric intake from <1000 kcal to >2000 kcal per day, leading to the development of electrolyte imbalances. This change is a classic trigger for refeeding syndrome.
Immediate ECG: To assess for any cardiac arrhythmias due to electrolyte imbalances, particularly hypokalemia and hypomagnesemia, which can prolong the QT interval and lead to dangerous arrhythmias.
Urinary Electrolytes and Diuretic Screen: To rule out renal causes of electrolyte loss and confirm the absence of diuretic use.
Continuous Cardiac Monitoring: Given the risk of arrhythmias, continuous monitoring is essential until electrolyte levels are stabilized.
Thiamine Supplementation: Administer thiamine to prevent Wernicke's encephalopathy, which can occur in the context of refeeding syndrome.
Multidisciplinary Approach: Involve a dietitian, psychiatrist, and an eating disorder specialist to manage the patient's nutritional rehabilitation safely and address underlying psychiatric issues.
Refeeding Syndrome: This condition occurs when reintroducing nutrition to malnourished patients, leading to shifts in electrolytes and fluids. It is crucial to start nutritional rehabilitation slowly and monitor electrolytes closely to prevent complications such as cardiac arrhythmias and neurological issues. Always consider thiamine supplementation to prevent Wernicke's encephalopathy in at-risk patients.
User: On examination, the patient's temperature was 36.8°C, her blood pressure 116/93 mm Hg, her pulse 132 beats per minute, her respiratory rate 18 breaths per minute, and her oxygen saturation 100% while breathing ambient air. Her weight was 55.7 kg, and her BMI 21.5. She appeared alert and anxious. A cardiac examination showed tachycardia, with normal S1 and S2 sounds and no murmurs, rubs, or gallops. The results of pulmonary, abdominal, musculoskeletal, neurologic, and dermatologic examinations were normal. There was no edema of the sacrum or the legs, nor was there any hypertrophy of the parotid gland, dental erosion, or calloused knuckles to suggest self-induced vomiting.
Hello, Chief Resident here.
The physical examination provides critical data that shifts our diagnostic focus:
1. Significant Tachycardia (132 bpm): This is disproportionate to her blood pressure (116/93 mm Hg) and suggests either a compensatory response to volume depletion, an autonomic manifestation of refeeding, or a direct effect of electrolyte instability.
2. Narrow Pulse Pressure (23 mm Hg): A blood pressure of 116/93 mm Hg indicates a high diastolic pressure and narrow pulse pressure, often seen in states of high systemic vascular resistance or decreased stroke volume (e.g., dehydration or early cardiac dysfunction).
3. Absence of Purging Stigmata: The lack of parotid hypertrophy, dental erosion, or Russell’s sign (calloused knuckles) lowers the clinical suspicion for chronic vomiting, though it does not rule out diuretic or laxative abuse.
4. Weight Discrepancy: Her weight is now 55.7 kg, which is a decrease from the 59 kg reported previously, despite the reported 3.2 kg gain at the start of the program. This suggests significant fluid fluctuations.
Immediate Management: The patient requires IV thiamine (before any further glucose/calories) and cautious, slow electrolyte replacement. Caloric intake should be standardized and supervised to prevent further shifts.
Hello Attending Consultant here.
Critique of resident plan (6 points):
Narrow pulse pressure misinterpretation: 116/93 mm Hg yields pulse pressure of 23 mm Hg; this is not “high diastolic” but reflects low stroke volume—most consistent with intravascular volume contraction or early refeeding cardiomyopathy, not high SVR; recalibrate volume assessment accordingly.
Tachycardia probability weighting flawed: Sinus tachycardia at 132 bpm in the context of acute caloric escalation is far more likely refeeding-related (insulin-driven catecholamine surge + thiamine deficit) than primary SSRI effect or pseudo-Bartter; lower diuretic-abuse likelihood to <15 % given absent edema and normal exam.
Omitted urgent thiamine administration: Resident correctly identifies risk but fails to mandate immediate 500 mg IV thiamine before any dextrose-containing fluids or further caloric load; this is non-negotiable to avert Wernicke or high-output cardiac failure.
Incomplete ECG/telemetry directive: Specify request for QTc (Fridericia preferred in tachycardia), T-wave morphology, and serial tracings; telemetry alone is insufficient without explicit arrhythmia protocol.
Urine studies panel incomplete: Add urine osmolality, urine pH, and serum–urine osmolality gap; TTKG is helpful but less discriminative than urine chloride-to-creatinine ratio when purging is covert.
Missing refeeding-specific labs and monitoring: No mention of daily prealbumin, CRP, or 6-hourly glucose/electrolytes for first 72 h; also omit baseline echocardiogram if tachycardia persists after Mg and PO₄ correction.
No explicit caloric titration protocol: State start at 10–15 kcal/kg/day (≈550–850 kcal) with 20–30 % increase every 48–72 h only after electrolytes stabilize; resident’s “standardized and supervised” is too vague for safety.
Expert:
Hello, Expert Clinician here.
The clinical presentation is most consistent with Refeeding Syndrome, characterized by electrolyte imbalances (hypokalemia, hypophosphatemia, hypomagnesemia) and cardiovascular symptoms (tachycardia) following rapid nutritional rehabilitation.
Refeeding Syndrome:
- Fits: The patient increased caloric intake significantly, leading to rapid weight gain and the classic triad of electrolyte disturbances. The timeline and symptoms (tachycardia, anxiety) align with this condition.
- Does Not Fit: Persistent hypokalemia despite supplementation could suggest another underlying issue, but the overall picture is consistent with refeeding syndrome.
Surreptitious Diuretic or Laxative Abuse:
- Fits: Persistent hypokalemia and hypomagnesemia could be due to ongoing purging behaviors, which are common in eating disorders.
- Does Not Fit: The patient denies these behaviors, and hypophosphatemia is more indicative of refeeding syndrome.
Pseudo-Bartter Syndrome:
- Fits: This condition can mimic refeeding syndrome in patients with eating disorders who have stopped purging behaviors, leading to rebound fluid and electrolyte shifts.
- Does Not Fit: The absence of purging stigmata and the context of recent nutritional rehabilitation make refeeding syndrome more likely.
The key pivot in this case is the rapid increase in caloric intake from <1000 kcal to >2000 kcal per day, leading to the development of electrolyte imbalances and cardiovascular symptoms. This change is a classic trigger for refeeding syndrome.
Immediate ECG and Continuous Telemetry: To assess for any cardiac arrhythmias due to electrolyte imbalances, particularly hypokalemia and hypomagnesemia, which can prolong the QT interval and lead to dangerous arrhythmias.
Thiamine Supplementation: Administer thiamine (500 mg IV) immediately to prevent Wernicke's encephalopathy and potential cardiac complications associated with refeeding syndrome.
Urinary Electrolytes and Diuretic Screen: To rule out renal causes of electrolyte loss and confirm the absence of diuretic use.
Daily Monitoring of Electrolytes and Glucose: Frequent monitoring is essential to adjust supplementation and caloric intake safely.
Multidisciplinary Approach: Involve a dietitian, psychiatrist, and an eating disorder specialist to manage the patient's nutritional rehabilitation safely and address underlying psychiatric issues.
Refeeding Syndrome: This condition occurs when reintroducing nutrition to malnourished patients, leading to shifts in electrolytes and fluids. It is crucial to start nutritional rehabilitation slowly and monitor electrolytes closely to prevent complications such as cardiac arrhythmias and neurological issues. Always consider thiamine supplementation to prevent Wernicke's encephalopathy in at-risk patients.
User: The pH of a venous blood sample was 7.45. The hemoglobin level was 13.1 g per deciliter, the TLC (total leukocyte count) was 15,950 per cubic millimeter, and the platelet count was 353,000 per cubic millimeter. The sodium level was 135 mmol per liter, potassium 2.55 mmol per liter, chloride 95 mmol per liter, bicarbonate 26 mmol per liter, anion gap 14 mmol per liter. KFT showed urea nitrogen 6 mg per deciliter and creatinine 0.4 mg per deciliter. The phosphorus level was 2.4 mg per deciliter, calcium 9.2 mg per deciliter, and magnesium 1.4 mg per deciliter.
The results of LFT and urinalysis were normal, as were the lactate level and the erythrocyte sedimentation rate. Toxicologic screens of the urine were negative for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates. A polymerase-chain-reaction assay for COVID-19 was negative. An electrocardiogram (ECG) showed sinus tachycardia with nonspecific changes in the ST-T wave and no U waves. The patient was admitted to the inpatient adolescent service for further nutritional rehabilitation, physiologic monitoring, and psychiatric assessment.
Resident:
Hello, Chief Resident here.
The laboratory data provides several critical insights that refine our diagnostic path:
1. Profound Hypokalemia (2.55 mmol/L): Despite previous supplementation, the potassium has dropped further.
2. Hypomagnesemia (1.4 mg/dL) and Hypophosphatemia (2.4 mg/dL): The triad of refeeding electrolytes is confirmed.
3. Leukocytosis (15,950/mm³): This is an unexpected finding. While it can be a non-specific stress response (demargination due to catecholamines/anxiety), it warrants consideration of occult infection or inflammation, though the ESR and lactate are normal.
4. Normal Anion Gap and Bicarbonate (26 mmol/L): The absence of metabolic alkalosis (high bicarbonate) and a normal urine pH (implied by "normal urinalysis") makes active vomiting less likely, as vomiting typically produces a contraction alkalosis.
5. Low Creatinine (0.4 mg/dL) and BUN (6 mg/dL): This reflects low muscle mass and potentially a state of protein-energy malnutrition, common in anorexia nervosa.
6. ECG Findings: Sinus tachycardia with nonspecific ST-T changes confirms the cardiac irritability but fortunately shows no immediate life-threatening arrhythmias or U-waves yet.
Management Strategy: The patient should be placed on a "low and slow" refeeding protocol (starting at 10-15 kcal/kg) with strict fluid restriction and aggressive electrolyte correction before advancing calories further. The leukocytosis should be monitored; if it does not resolve with stabilization, a chest X-ray or blood cultures may be considered.
Hello Attending Consultant here.
Critique of resident plan (6 points):
Overstated refeeding probability (80%): Persistent K 2.55 mmol/L after 20 mEq daily supplementation plus narrow pulse pressure and leukocytosis favor covert purging or diuretic use over pure intracellular shift; recalibrate to 50 % and elevate surreptitious behavior to 30 %.
Missing immediate thiamine dosing: Resident correctly identifies need but omits explicit 500 mg IV thiamine STAT before any carbohydrate load; delay risks Wernicke or high-output failure given HR 132 bpm.
Urine studies panel incomplete: Order urine chloride, TTKG, urine diuretic screen, and urine osmolality simultaneously; normal serum HCO3 26 mmol/L does not exclude intermittent vomiting when urine Cl is low (<15 mmol/L).
Leukocytosis under-addressed: 15 950/mm³ with normal ESR/lactate still requires CRP, blood cultures, and chest radiograph within 12 h; cannot be dismissed as “stress” until infection is excluded in a refeeding patient.
Refeeding protocol too vague: Specify start at 10 kcal/kg/day (≈550 kcal), advance by ≤300 kcal every 48 h only after PO4 >2.5 mg/dL, K >3.0 mmol/L, and Mg >1.8 mg/dL; resident’s “low and slow” lacks quantifiable triggers.
ECG and cardiac evaluation insufficient: Sinus tachycardia with nonspecific ST-T changes plus HR 132 bpm mandates formal QTc calculation (Fridericia), daily ECGs, and echocardiogram within 24 h to rule out refeeding cardiomyopathy; telemetry alone is inadequate.
No psychiatry–nutrition handoff timeline: Admission note must document same-day goals-of-care meeting with eating-disorder team before any caloric titration; resident plan lacks explicit multidisciplinary activation.
Expert:
Hello, Expert Clinician here.
The clinical presentation remains most consistent with Refeeding Syndrome, given the electrolyte imbalances (hypokalemia, hypophosphatemia, hypomagnesemia) and the context of rapid nutritional rehabilitation. However, the persistent hypokalemia despite supplementation and leukocytosis warrant careful consideration of other contributing factors, such as covert purging or diuretic use.
Refeeding Syndrome:
- Fits: The patient increased caloric intake significantly, leading to rapid weight gain and the classic triad of electrolyte disturbances. The timeline and symptoms (tachycardia, anxiety) align with this condition.
- Does Not Fit: Persistent hypokalemia despite supplementation suggests another underlying issue, such as covert purging or diuretic use.
Surreptitious Diuretic or Laxative Abuse:
- Fits: Persistent hypokalemia and hypomagnesemia could be due to ongoing purging behaviors, which are common in eating disorders.
- Does Not Fit: The patient denies these behaviors, and the normal bicarbonate level makes chronic vomiting less likely.
Occult Infection:
- Fits: Leukocytosis (15,950/mm³) could indicate an underlying infection, although the patient is afebrile with a normal ESR and lactate.
- Does Not Fit: The absence of clinical signs of infection makes this less likely, but it cannot be completely ruled out.
The key pivot in this case is the rapid increase in caloric intake from <1000 kcal to >2000 kcal per day, leading to the development of electrolyte imbalances and cardiovascular symptoms. The persistent hypokalemia despite supplementation and leukocytosis require further investigation to rule out other contributing factors.
Immediate Thiamine Supplementation: Administer 500 mg IV thiamine immediately to prevent Wernicke's encephalopathy and potential cardiac complications associated with refeeding syndrome.
Urinary Electrolytes and Diuretic Screen: To rule out renal causes of electrolyte loss and confirm the absence of diuretic use. Specifically request urine chloride, TTKG, and urine osmolality.
Serial Electrolyte Monitoring (Q6-Q8 hours): To guide aggressive but cautious IV and oral replacement.
Echocardiogram: Given the persistent tachycardia and the risk of refeeding-related cardiomyopathy or "wet beriberi" (high-output heart failure).
Multidisciplinary Approach: Involve a dietitian, psychiatrist, and an eating disorder specialist to manage the patient's nutritional rehabilitation safely and address underlying psychiatric issues.
Evaluate for Infection: Conduct a CRP, blood cultures, and chest radiograph to rule out occult infection as a cause of leukocytosis.
Refeeding Syndrome: This condition occurs when reintroducing nutrition to malnourished patients, leading to shifts in electrolytes and fluids. It is crucial to start nutritional rehabilitation slowly and monitor electrolytes closely to prevent complications such as cardiac arrhythmias and neurological issues. Always consider thiamine supplementation to prevent Wernicke's encephalopathy in at-risk patients.
User: The hypophosphatemia resolved with further oral supplementation and did not recur. However, the hypokalemia persisted (lowest level, 2.51 mmol per liter), and the hypomagnesemia recurred intermittently (lowest level, 1.1 mg per deciliter) despite supervised supplementation with enteral potassium chloride of up to 60 mEq three times daily and magnesium oxide up to 800 mg three times daily. The patient also received parenteral boluses of both potassium chloride and magnesium sulfate frequently. She remained hypochloremic (lowest level, 89 mmol per liter), and hyponatremia developed, with sodium levels declining to 132 mmol per liter despite adequate intake and administration of isotonic intravenous fluids. Her serum bicarbonate level was intermittently elevated, reaching a high of 32 mmol per liter, with persistent mild alkalemia (the pH increased to 7.488 with venous blood gas measurement). Careful questioning and inspection of her hospital room indicated that she was not taking diuretic medication. Serial ECGs showed changes consistent with hypokalemia. Given her persistent need for aggressive repletion of electrolytes, she was transferred to an intensive care step-down unit and the nephrology team was consulted.
Resident:
Hello, Chief Resident here.
The clinical picture has shifted significantly with the failure of standard refeeding management:
1. Refractory Hypokalemia and Hypomagnesemia: Despite massive doses of oral (180 mEq/day K) and parenteral supplementation, the patient remains profoundly depleted. This is no longer consistent with a simple intracellular shift from refeeding.
2. Development of Metabolic Alkalosis (pH 7.48, HCO3 32): This is a classic "contraction alkalosis" or "metabolic alkalosis with hypokalemia," which strongly points toward either surreptitious vomiting or a renal tubulopathy.
3. Hypochloremia (89 mmol/L) and Hyponatremia (132 mmol/L): The combination of low chloride and metabolic alkalosis is highly suggestive of upper GI loss (vomiting) or diuretic use.
4. Resolution of Hypophosphatemia: This confirms that the refeeding component of her illness has likely stabilized, leaving a secondary process driving the ongoing potassium and magnesium loss.
5. Inpatient Supervision: The persistence of these findings while hospitalized and under "careful inspection" makes surreptitious behavior more difficult but not impossible, or suggests an intrinsic renal/genetic cause.
Management Strategy: Transition to aggressive IV replacement of magnesium and potassium via central access if necessary. If Gitelman is suspected, consider adding a potassium-sparing diuretic (e.g., Amiloride or Spironolactone) which, paradoxically, can help stabilize potassium levels in these patients. Strict 1-to-1 nursing observation may be required to definitively rule out purging.
Hello Attending Consultant here.
Critique of resident plan (6 points):
Probability weighting inverted: Persistent chloride-resistant metabolic alkalosis (HCO3 32 mmol/L, pH 7.488), profound urinary K/Mg wasting despite 180 mEq/day supplementation, and hypocalciuria (if measured) make Gitelman syndrome far more likely (60 %) than surreptitious vomiting (20 %); vomiting typically produces low urine Cl (<15 mmol/L) and should not require such massive ongoing repletion once vomiting ceases.
Urine chloride ordered without paired renin/aldosterone or simultaneous serum values: Must obtain spot urine Cl, Na, K, creatinine, Ca, together with plasma renin, aldosterone, and Mg to calculate TTKG (>4 in alkalosis confirms renal K wasting) and transtubular Mg gradient; isolated UCl is insufficient for chloride-resistant vs responsive classification.
Omitted urine diuretic assay timing: Send comprehensive LC-MS/MS urine screen for thiazides, loop diuretics, and carbonic-anhydrase inhibitors immediately on transfer to step-down unit before any further IV K/Mg boluses that could confound results.
No echocardiogram or telemetry escalation: Serial ECGs show hypokalemic changes; with HR previously 132 bpm and now refractory electrolytes, order urgent bedside echo to exclude refeeding cardiomyopathy or high-output failure and place on continuous telemetry with daily QTc (Fridericia) measurement.
Magnesium repletion route suboptimal: Oral Mg oxide has <4 % bioavailability and causes diarrhea; switch to IV Mg sulfate 2–4 g q6–8h targeting serum Mg >1.8 mg/dL before any further K repletion, as hypomagnesemia perpetuates kaliuresis.
Genetic testing premature and caloric plan absent: Defer SLC12A3 sequencing until urine diuretic screen is negative, urine Ca/Cr <0.02, and renin/aldosterone are elevated; simultaneously restart structured refeeding at 12–15 kcal/kg/day with daily prealbumin, phosphate, and glucose monitoring per ASPEN guidelines.
Multidisciplinary gap: Immediate activation of eating-disorder behavioral protocol with 1:1 observation and psychiatry consult is mandatory; resident plan lacks explicit handoff timeline to nephrology, nutrition, and adolescent medicine teams.
Expert:
Hello, Expert Clinician here.
The clinical presentation is now most consistent with Gitelman Syndrome, a renal tubulopathy characterized by hypokalemia, hypomagnesemia, metabolic alkalosis, and hypocalciuria. The persistent electrolyte imbalances despite aggressive supplementation and the metabolic alkalosis with hypochloremia strongly suggest this diagnosis.
Gitelman Syndrome:
- Fits: The persistent hypokalemia, hypomagnesemia, metabolic alkalosis, and hypochloremia are classic for Gitelman syndrome. The need for aggressive electrolyte repletion and the absence of diuretic use or purging behaviors further support this.
- Does Not Fit: Typically presents earlier in life, but can be unmasked or exacerbated by stressors such as nutritional rehabilitation.
Surreptitious Purging (Vomiting):
- Fits: The biochemical profile could mimic purging, but the absence of physical stigmata and the hospital setting make this less likely.
- Does Not Fit: Persistent electrolyte imbalances despite supervision and the lack of metabolic alkalosis resolution argue against this.
Surreptitious Diuretic Abuse:
- Fits: The biochemical profile could mimic diuretic use, but careful room inspection and the hospital setting make this less likely.
- Does Not Fit: The absence of diuretics in toxicology screens and the persistent electrolyte imbalances despite supervision argue against this.
The key pivot in this case is the persistent metabolic alkalosis with hypokalemia and hypomagnesemia despite aggressive supplementation and the absence of purging or diuretic use, which strongly suggests a renal tubular disorder like Gitelman syndrome.
Urinary Electrolytes and Calcium-to-Creatinine Ratio: Measure urine chloride, sodium, potassium, creatinine, and calcium to differentiate between Gitelman and Bartter syndromes. Gitelman syndrome typically presents with hypocalciuria (urine Ca/Cr ratio <0.02).
Comprehensive Urine Diuretic Screen: Send a specialized urine assay for thiazides and loop diuretics to definitively rule out surreptitious use.
Plasma Renin and Aldosterone Levels: Elevated levels would confirm secondary hyperaldosteronism, consistent with Gitelman syndrome.
Genetic Testing for SLC12A3: If urine studies support Gitelman syndrome and diuretic screen is negative, proceed with genetic testing for confirmation.
Aggressive IV Magnesium and Potassium Replacement: Switch to IV magnesium sulfate for better bioavailability and continue potassium chloride supplementation. Consider adding a potassium-sparing diuretic like amiloride to help retain potassium.
Echocardiogram and Continuous Telemetry: Given the persistent tachycardia and electrolyte imbalances, perform an echocardiogram to assess cardiac function and monitor QTc interval on telemetry.
Multidisciplinary Approach: Ensure involvement of nephrology, nutrition, psychiatry, and an eating disorder specialist to manage the patient's complex needs.
Gitelman Syndrome: This autosomal recessive disorder is characterized by hypokalemia, hypomagnesemia, metabolic alkalosis, and hypocalciuria. It results from mutations in the SLC12A3 gene, affecting the thiazide-sensitive Na-Cl cotransporter in the distal convoluted tubule. Management focuses on electrolyte repletion and symptom control, often requiring high doses of oral or IV supplements.
User: Assessment of urinary electrolytes showed a sodium level of 136 mmol per liter (expected level in hyponatremia attributable to hypovolemia, <40 mmol per liter), a potassium level of more than 100 mmol per liter (expected level in hypokalemia, <20 mmol per liter), a chloride level of 193 mmol per liter (expected level in hypochloremia, <40 mmol per liter), and a creatinine level of 31 mg per deciliter. The ratio of urinary calcium to creatinine (both measured in milligrams) was 0.06 (normal level, <0.24 mg calcium per milligram of creatinine). A subsequent urinary phosphorus level was 11.3 mg per deciliter, yielding tubular resorption of phosphate of more than 96%.
Resident:
Hello, Chief Resident here.
The urinary electrolyte data provides the definitive "smoking gun" for the localization of the electrolyte loss:
1. Inappropriate Renal Wasting: In the setting of profound serum hypokalemia (2.5 mmol/L), the urine potassium is >100 mmol/L (expected <20). In the setting of hyponatremia and hypochloremia, the urine chloride is massively elevated at 193 mmol/L (expected <40).
2. Chloride-Resistant Metabolic Alkalosis: The high urinary chloride (>40 mmol/L) definitively rules out vomiting/purging as the primary driver of the current state, as vomiting would cause the kidneys to avidly retain chloride (UCl < 20).
3. Normal Urinary Calcium-to-Creatinine Ratio (0.06): This is a pivotal finding. Gitelman syndrome is characterized by hypocalciuria (typically <0.02 mg/mg). A ratio of 0.06 is within the normal range, which points away from Gitelman and more toward either Bartter Syndrome or Diuretic Abuse.
4. High Tubular Resorption of Phosphate (>96%): This confirms that the kidneys are appropriately conserving phosphate, reinforcing that the initial hypophosphatemia was indeed due to intracellular shift (refeeding) rather than a renal tubular defect.
Management Strategy: Continue aggressive IV potassium and magnesium replacement. If diuretic abuse is confirmed, the primary treatment is psychiatric intervention and strict supervision. If a tubulopathy is confirmed, long-term management with NSAIDs (for Bartter) or potassium-sparing diuretics and lifelong supplementation will be required.
Hello Attending Consultant here.
Critique of resident plan (6 points):
Probability miscalibrated: High urine Cl (193 mmol/L), K (>100 mmol/L), and normal Ca/Cr ratio (0.06) with chloride-resistant alkalosis make Bartter syndrome (type III) or occult loop-diuretic use far more likely (combined 75 %) than Gitelman (now <5 %); resident over-weighted diuretic abuse while under-weighting genetic tubulopathy.
Urine diuretic screen timing critical but unspecified: Order LC-MS/MS assay on a fresh, supervised sample immediately before next IV K/Mg bolus; false-negative rate rises sharply once supplementation begins.
Missing transtubular potassium gradient (TTKG) and fractional excretion calculations: With urine creatinine 31 mg/dL, calculate TTKG (>7 expected in renal K wasting) and FE_K (>6.5 %); these quantify severity of distal tubular defect and should be documented in note.
No renin–aldosterone axis confirmation: Plasma renin and aldosterone must be drawn simultaneously with urine studies to demonstrate secondary hyperaldosteronism; omission leaves differential between Bartter and surreptitious diuretic incomplete.
Calcium-to-creatinine ratio interpretation incomplete: Value 0.06 rules out classic Gitelman (typically <0.02) but does not exclude all variants; repeat fasting ratio plus 24-h urinary calcium excretion is required for precision.
Cardiac and refeeding oversight: Persistent hypokalemia (2.51 mmol/L) with ECG changes demands daily Fridericia QTc, continuous telemetry, and echocardiogram within 12 h; caloric advancement must remain frozen at 10–12 kcal/kg/day until electrolytes stabilize.
Multidisciplinary activation absent: Immediate joint huddle with nephrology, adolescent psychiatry, and eating-disorder dietitian is mandatory before step-down transfer; resident plan lacks explicit 24-h timeline.
Expert:
Hello, Expert Clinician here.
The clinical presentation, particularly the urinary electrolyte profile, is most consistent with Bartter Syndrome, specifically Type III (classic Bartter syndrome). This renal tubular disorder is characterized by hypokalemia, metabolic alkalosis, and normal to high urinary calcium excretion, mimicking loop diuretic use.
Bartter Syndrome (Type III):
- Fits: The high urinary chloride, high urinary potassium, and normal urinary calcium-to-creatinine ratio align with Bartter syndrome. The persistent electrolyte imbalances despite aggressive supplementation and the metabolic alkalosis further support this diagnosis.
- Does Not Fit: Typically presents earlier in life, but milder forms can present later, especially under stressors like nutritional rehabilitation.
Surreptitious Diuretic Abuse:
- Fits: The biochemical profile could mimic diuretic use, but the hospital setting and careful room inspection make this less likely.
- Does Not Fit: The absence of diuretics in toxicology screens and the persistent electrolyte imbalances despite supervision argue against this.
Gitelman Syndrome:
- Fits: The hypokalemia and hypomagnesemia initially suggested Gitelman, but the normal urinary calcium-to-creatinine ratio and high urinary chloride are inconsistent with this diagnosis.
The key pivot in this case is the urinary electrolyte profile, particularly the high urinary chloride and potassium levels, which indicate renal tubular wasting rather than gastrointestinal loss or surreptitious diuretic use.
Comprehensive Urine Diuretic Screen (LC-MS/MS): Obtain a fresh, supervised sample to definitively rule out diuretic use. This should be done immediately before any further electrolyte supplementation.
Plasma Renin and Aldosterone Levels: To confirm secondary hyperaldosteronism, which is expected in Bartter syndrome.
Genetic Testing for Bartter Syndrome: If the diuretic screen is negative, proceed with genetic testing for mutations in genes associated with Bartter syndrome, such as CLCNKB.
Transtubular Potassium Gradient (TTKG) and Fractional Excretion of Potassium (FE_K): Calculate these to quantify the severity of renal potassium wasting.
Echocardiogram and Continuous Telemetry: Given the persistent hypokalemia and ECG changes, perform an echocardiogram to assess cardiac function and monitor the QTc interval on telemetry.
Multidisciplinary Approach: Involve nephrology, psychiatry, and an eating disorder specialist to manage the patient's complex needs.
Bartter Syndrome: This autosomal recessive disorder is characterized by hypokalemia, metabolic alkalosis, and normal to high urinary calcium excretion. It results from mutations affecting ion transport in the thick ascending limb of the loop of Henle. Management focuses on electrolyte repletion and symptom control, often requiring high doses of oral or IV supplements and sometimes NSAIDs to reduce renal prostaglandin production.
User: The results of renal ultrasonography were normal. The patient's serum renin activity was elevated, and the aldosterone level was normal. The results of a corticotropin stimulation test were normal. Additional history was obtained and revealed that the patient had had salt-craving behaviors since early childhood (e.g., drinking pickle juice and licking the salt off salty snacks). She also reported frequent nocturia as well as nocturnal enuresis into early adolescence. Furthermore, she reported symptomatic orthostasis, with at least one syncopal episode attributed to orthostatic hypotension. Consultation with the genetics department was pursued out of concern for inherited causes of distal tubulopathies. Her family history was remarkable for a maternal aunt with unexplained hypokalemia who takes magnesium supplements. Her parents were noted to be first cousins.
Resident:
Hello, Chief Resident here.
The case has reached a diagnostic tipping point with several pathognomonic historical and laboratory clues:
1. Consanguinity: The parents are first cousins, which dramatically increases the probability of an autosomal recessive disorder.
2. Lifelong Symptoms: Salt-craving (pickle juice), nocturia, and nocturnal enuresis into adolescence are classic indicators of a chronic renal salt-wasting state (polyuria/polydipsia) that predates her eating disorder.
3. Renin-Aldosterone Dissociation: Elevated renin with a "normal" aldosterone level in the face of profound hypokalemia is a subtle but important finding. While aldosterone is typically high in Bartter/Gitelman, severe hypokalemia can actually suppress aldosterone secretion from the adrenal cortex, even when renin is high.
4. Family History: A maternal aunt with unexplained hypokalemia suggests a familial cluster of a tubulopathy.
5. Normal Renal Ultrasound: Rules out nephrocalcinosis, which is more common in Bartter Types I and II, but often absent in Type III and Gitelman.
Management Strategy: The patient should be treated as having a primary renal salt-wasting syndrome. Her "anorexia" may have been partially driven by the polyuria and malaise of her undiagnosed tubulopathy. Nutritional rehabilitation must proceed with the understanding that her electrolyte requirements are baseline-high and will remain so for life.
Attending:
Hello Attending Consultant here.
Critique of resident plan (6 points):
Probability weighting misaligned with consanguinity: With first-cousin parents and lifelong salt-craving/enuresis, the probability of an autosomal recessive tubulopathy is >95 %; surreptitious behavior should be downgraded to <1 %.
Gitelman vs. Bartter Type III distinction: While salt-craving is common to both, nocturnal enuresis into early adolescence and symptomatic orthostasis/syncope are more characteristic of the profound salt-wasting seen in Bartter syndrome (specifically Type III/Classic) than the typically milder Gitelman; adjust Bartter probability to 60 % and Gitelman to 35 %.
Renin–aldosterone interpretation: Resident correctly notes K-mediated aldosterone suppression but fails to emphasize that elevated renin confirms a primary salt-wasting state; this effectively rules out Liddle syndrome or mineralocorticoid excess.
Genetic testing specification: Request a targeted "Renal Tubulopathy Panel" including SLC12A3, CLCNKB, SLC12A1, KCNJ1, and BSND; whole-exome sequencing is unnecessary and slower for this specific phenotype.
Omitted prostaglandin E2 (PGE2) measurement: In Bartter syndrome, urinary PGE2 is often markedly elevated; this can support the diagnosis and justify the use of NSAIDs before genetic results return.
NSAID trial caution: While resident suggests an NSAID trial, must specify monitoring for gastric irritation and renal function (creatinine), especially in a patient with a history of restrictive eating and potential low baseline GFR.
Multidisciplinary transition: The focus must now shift from "eating disorder management" to "chronic tubulopathy education"; the patient’s "anorexia" may have been a misdiagnosis of her chronic malaise and salt-wasting. Ensure a formal handoff to a specialized adult nephrology clinic for long-term transition.
Expert:
Expert:
Hello, Expert Clinician here.
The clinical presentation, including the lifelong history of salt-craving, nocturia, enuresis, and orthostatic hypotension, combined with the family history of consanguinity and unexplained hypokalemia, is most consistent with Bartter Syndrome Type III (Classic Bartter Syndrome). This autosomal recessive disorder results from mutations in the CLCNKB gene, leading to salt wasting in the thick ascending limb of the loop of Henle.
Bartter Syndrome Type III:
- Fits: The lifelong salt-craving, enuresis, orthostatic hypotension, and elevated renin are classic for Bartter syndrome. The normal urinary calcium-to-creatinine ratio and the severity of symptoms further support this diagnosis.
- Does Not Fit: Often presents earlier in life, but milder forms can present in adolescence or even adulthood.
Gitelman Syndrome:
- Fits: The hypokalemia, hypomagnesemia, and salt-craving are common in Gitelman syndrome.
- Does Not Fit: The normal urinary calcium-to-creatinine ratio and the severity of salt-wasting symptoms (enuresis, syncope) are more characteristic of Bartter syndrome.
Surreptitious Diuretic Abuse:
- Fits: The biochemical profile could mimic diuretic use.
- Does Not Fit: The lifelong history, consanguinity, and family history strongly point toward a genetic cause.
The key pivot in this case is the lifelong history of salt-craving and enuresis, combined with the family history of consanguinity and unexplained hypokalemia, which strongly suggests an inherited renal tubulopathy like Bartter syndrome.
Targeted Genetic Testing: Perform a renal tubulopathy panel focusing on mutations in CLCNKB (Bartter Type III) and SLC12A3 (Gitelman).
Urinary Prostaglandin E2 (PGE2) Level: Elevated levels can support a diagnosis of Bartter syndrome and guide the use of NSAIDs.
24-Hour Urine Collection: To accurately quantify calcium and magnesium excretion and confirm the renal wasting pattern.
NSAID Trial (e.g., Indomethacin): If Bartter syndrome is confirmed, NSAIDs can help reduce salt wasting and improve potassium levels. Monitor renal function and gastric health closely.
Multidisciplinary Approach: Involve nephrology, genetics, and psychiatry to manage the patient's chronic condition and address the psychological impact of her diagnosis.
Bartter Syndrome Type III: This classic form of Bartter syndrome results from mutations in the
Hello Attending Consultant here.
Critique of resident plan (6 points):
Probability weighting reversed: Consanguinity, childhood-onset salt craving, lifelong nocturia/enuresis, orthostasis with syncope, maternal aunt with hypokalemia, and high renin with inappropriately normal aldosterone shift diagnosis to classic Bartter syndrome (CLCNKB mutation) at ~75 % probability; Gitelman now <20 % given normal (not low) urine Ca/Cr ratio of 0.06.
Genetic panel too broad and slow: Order targeted next-generation sequencing panel for salt-losing tubulopathies (CLCNKB, SLC12A1, KCNJ1, BSND first) rather than whole-exome or generic “tubulopathy panel”; results guide therapy within days.
Missing urinary PGE2 and 24-h calcium excretion: Quantify urinary prostaglandin E2 (elevated in Bartter) and 24-h urinary calcium (<4 mg/kg/day expected) to strengthen Bartter diagnosis before genetics return; spot Ca/Cr alone is insufficient.
Aldosterone interpretation incomplete: “Normal” aldosterone in setting of volume depletion and high renin is pathologically low; calculate aldosterone-renin ratio and repeat after K correction to unmask secondary hyperaldosteronism.
No immediate indomethacin trial: Initiate low-dose indomethacin (1–2 mg/kg/day) with gastric protection once PGE2 confirmed elevated or while awaiting genetics; this is disease-modifying in Bartter Type III and reduces supplemental electrolyte burden.
Refeeding and cardiac oversight omitted: Freeze caloric advancement at 12 kcal/kg/day; continue daily Fridericia QTc, continuous telemetry, and echocardiogram until K >3.0 mmol/L and Mg >1.8 mg/dL to prevent arrhythmia in a salt-wasting cardiomyopathy-prone state.
Diagnostic reframing absent: Resident fails to state that anorexia nervosa behaviors were likely secondary to chronic polyuria/malaise of undiagnosed Bartter; immediate transition plan to adult nephrology and genetic counseling required.
Expert:
Hello, Expert Clinician here.
The clinical presentation, including the lifelong history of salt-craving, nocturia, enuresis, orthostatic hypotension, and the family history of consanguinity and unexplained hypokalemia, is most consistent with Bartter Syndrome Type III (Classic Bartter Syndrome). This autosomal recessive disorder results from mutations in the CLCNKB gene, leading to salt wasting in the thick ascending limb of the loop of Henle.
Bartter Syndrome Type III:
- Fits: The lifelong salt-craving, enuresis, orthostatic hypotension, and elevated renin are classic for Bartter syndrome. The normal urinary calcium-to-creatinine ratio and the severity of symptoms further support this diagnosis.
- Does Not Fit: Often presents earlier in life, but milder forms can present in adolescence or even adulthood.
Gitelman Syndrome:
- Fits: The hypokalemia, hypomagnesemia, and salt-craving are common in Gitelman syndrome.
- Does Not Fit: The normal urinary calcium-to-creatinine ratio and the severity of salt-wasting symptoms (enuresis, syncope) are more characteristic of Bartter syndrome.
Surreptitious Diuretic Abuse:
- Fits: The biochemical profile could mimic diuretic use.
- Does Not Fit: The lifelong history, consanguinity, and family history strongly point toward a genetic cause.
The key pivot in this case is the lifelong history of salt-craving and enuresis, combined with the family history of consanguinity and unexplained hypokalemia, which strongly suggests an inherited renal tubulopathy like Bartter syndrome.
Targeted Genetic Testing: Perform a renal tubulopathy panel focusing on mutations in CLCNKB (Bartter Type III) and SLC12A3 (Gitelman).
Urinary Prostaglandin E2 (PGE2) Level: Elevated levels can support a diagnosis of Bartter syndrome and guide the use of NSAIDs.
24-Hour Urine Collection: To accurately quantify calcium and magnesium excretion and confirm the renal wasting pattern.
NSAID Trial (e.g., Indomethacin): If Bartter syndrome is confirmed, NSAIDs can help reduce salt wasting and improve potassium levels. Monitor renal function and gastric health closely.
Multidisciplinary Approach: Involve nephrology, genetics, and psychiatry to manage the patient's chronic condition and address the psychological impact of her diagnosis.
Bartter Syndrome Type III: This classic form of Bartter syndrome results from mutations in the CLCNKB gene, leading to defective chloride reabsorption in the thick ascending limb of the loop of Henle. It is characterized by hypokalemia, metabolic alkalosis, and normal to high urinary calcium excretion. Management includes electrolyte repletion, NSAIDs to reduce renal prostaglandin production, and addressing any associated growth or developmental issues.
User: The patient continued to require intensive electrolyte supplementation. Given the high clinical suspicion for a hypokalemic tubulopathy and the inadequate response to supplements alone, amiloride was started at a dose of 5 mg daily, with increases in dose scheduled over 4 days with the goal of obtaining a dose of 20 mg twice daily. On this medication, the patient's potassium level normalized, and she was transitioned to oral electrolyte supplements. She was discharged in stable condition with prescriptions for magnesium oxide, potassium chloride, and sodium chloride and referred to a genetics clinic for further evaluation. While at the clinic, the family agreed to have a gene panel evaluated for the presence of a hereditary tubulopathy. The results provided the basis for a molecular diagnosis of Gitelman's syndrome owing to a homozygous pathogenic variant in SLC12A3, termed c.2869A→T (p.Lys947Ter). The patient continued to maintain excellent adherence to the regimen of amiloride and electrolyte supplementation, and her electrolyte levels remained stable at follow-up 15 months after her original presentation.
Resident:
Hello, Chief Resident here.
The case concludes with a molecular diagnosis that provides a definitive explanation for the patient's complex presentation:
1. Molecular Diagnosis: Homozygous pathogenic variant in SLC12A3 (c.2869A→T; p.Lys947Ter), confirming Gitelman Syndrome.
2. Genetics and Consanguinity: The homozygosity of the variant is explained by the parents being first cousins, which is a classic setup for rare autosomal recessive disorders.
3. Therapeutic Response: The dramatic stabilization of potassium levels upon starting Amiloride (a potassium-sparing diuretic) is a key clinical finding. In Gitelman syndrome, amiloride blocks the epithelial sodium channel (ENaC) in the collecting duct, reducing the distal sodium delivery that drives potassium secretion.
4. Clinical Mimicry: This case highlights how a chronic genetic tubulopathy can be misdiagnosed as an eating disorder (Anorexia Nervosa) or surreptitious purging due to the overlapping biochemical profile (hypokalemia, alkalosis) and the patient's malaise/weight loss.
Gitelman Syndrome as a Great Mimicker: In adolescent females, the biochemical triad of hypokalemia, hypomagnesemia, and metabolic alkalosis is frequently attributed to eating disorders or purging. However, a history of lifelong salt-craving, nocturnal enuresis, or consanguinity should immediately trigger an evaluation for a genetic tubulopathy. Furthermore, refeeding syndrome can "unmask" these underlying defects by placing an anabolic demand on already depleted electrolyte stores. Always check a urinary calcium-to-creatinine ratio; while not always perfect, it remains a vital tool in differentiating Gitelman (low) from Bartter (normal/high).
Hello Attending Consultant here.
Critique of resident plan (6 points):
Diagnostic probability error: Resident retroactively assigns 100 % Gitelman only after genetic confirmation; pre-test probability should have been ~40 % given urine Ca/Cr ratio 0.06 (not frankly hypocalciuric) and severe childhood salt-wasting/enuresis more typical of Bartter type III.
Amiloride titration unsafe: Escalation to 20 mg BID over 4 days risks profound volume contraction and hypotension in a salt-wasting patient; standard starting dose is 5–10 mg daily with slower up-titration guided by daily weights, orthostatics, and serum K.
Missing renin–aldosterone follow-up: Elevated renin with inappropriately normal aldosterone should have prompted repeat measurement after K correction (>3.0 mmol/L) to demonstrate true secondary hyperaldosteronism expected in SLC12A3 loss-of-function.
Omitted urinary PGE2 and 24-h Ca excretion: These would have clarified Bartter vs Gitelman before genetics; spot Ca/Cr 0.06 is nondiagnostic and should have been followed by 24-h collection (<2 mg/kg/day supports Gitelman).
Refeeding oversight persists: No documentation of caloric stabilization at 12–15 kcal/kg/day or daily prealbumin/phosphate trends during amiloride initiation; refeeding risk remains until electrolytes are stable for 72 h.
Genetic and transition gaps: SLC12A3 c.2869A>T (p.Lys947Ter) is a nonsense variant causing complete loss of NCCT function; resident plan lacks counseling on lifelong high-NaCl diet, NSAID avoidance, and formal transition to adult nephrology/genetics clinic.
Mimicry teaching incomplete: Emphasize that Gitelman frequently masquerades as purging-type anorexia nervosa; orthostasis, enuresis since childhood, and consanguinity are red-flag historical features that should prompt early urine Ca/Cr and genetic referral rather than prolonged eating-disorder admission.
Expert:
Hello, Expert Clinician here.
The confirmed diagnosis of Gitelman Syndrome via genetic testing (homozygous pathogenic variant in SLC12A3) provides a definitive explanation for the patient's presentation. This autosomal recessive disorder results in defective thiazide-sensitive Na-Cl cotransporter function in the distal convoluted tubule, leading to hypokalemia, hypomagnesemia, and metabolic alkalosis.
Gitelman Syndrome as a Diagnostic Challenge: This condition often presents with symptoms that overlap with eating disorders, particularly in adolescent females. Key historical clues such as lifelong salt-craving, nocturnal enuresis, and a family history of similar symptoms should prompt consideration of a genetic tubulopathy. The urinary calcium-to-creatinine ratio is a valuable tool in differentiating Gitelman (typically low) from Bartter syndrome (normal to high), although it may not always be definitive. Genetic testing provides the ultimate confirmation and guides appropriate management.